Statins for Primary Prevention of XXXX in Elderly @entity1 : Systematic Review and Meta-Analysis.

@entity1 @entity64 @entity6 @entity73 @entity5925 @entity583 @entity925 @entity121 @entity65
BACKGROUND: Statins have been shown to be beneficial in primary and secondary prevention settings; however, their role in the elderly remains a clinical conundrum, given that age-related factors could alter the risk-benefit ratio of statin treatment. This study aimed to critically evaluate the efficacy and safety of statins for primary prevention of @entity65 ( @entity65 ) in the elderly. METHODS: We systematically reviewed randomized controlled trials comparing any statins with placebo or usual care for primary prevention of @entity65 in subjects aged >= 65 years. Relative risks (RRs) using a random effects model were calculated and sensitivity analyses were performed to assess the robustness of findings. RESULTS: Eight studies (n = 25,952) were included in the meta-analysis. Statins significantly reduced the risks of composite major adverse cardiovascular events (RR 0.82, 95% CI 0.74-0.92), nonfatal @entity583 [ @entity583 ] (0.75, 0.59-0.94) and total @entity583 (0.74, 0.61-0.90). Treatment effects of statins were statistically insignificant in fatal @entity583 (0.43, 0.09-2.01), @entity64 (fatal: 0.76, 0.24-2.45; nonfatal: 0.76, 0.53-1.11; total: 0.85, 0.68-1.06) and all-cause mortality (0.96, 0.88-1.04). Significant differences were not observed in @entity925 (0.88, 0.69-1.13), elevation of hepatic transaminases (0.98, 0.71-1.34), new-onset @entity6 (1.07, 0.77-1.48), serious adverse events (1.00, 0.97-1.04) and discontinuation due to adverse events (1.10, 0.85-1.42). The occurrence of @entity121 , @entity5925 and @entity73 was largely unreported in the included trials. CONCLUSIONS: From a risk-benefit perspective, there is a role of statins for the primary prevention of major adverse cardiovascular events in elderly @entity1 . Further studies are needed to ascertain the benefits of statins on fatal @entity583 , @entity64 and all-cause mortality.
